Nippon Paint Reportedly Offers Up to €7.5 Billion for Akzo Nobel Decorative Paints Business 
AstraZeneca Shares Sink After Wainua Trial Misses Key Heart Disease Goal 
Fast Retailing Raises Full-Year Forecast After Uniqlo Owner Beats Q3 Profit Estimates 
DOJ Grand Jury Investigates UAW President Shawn Fain Ahead of Union Election 
Apple Sues OpenAI, Former Employees Over Alleged Trade Secret Theft 
Samsung to Launch First Yongin Chip Plant by 2029 as South Korea Speeds Up Semiconductor Hub 
Levi Strauss Raises 2026 Outlook After Q2 Earnings Beat, Shares Drop Despite Strong Results 
Muji Owner Ryohin Keikaku Stock Soars After Raising Full-Year Earnings Forecast 
Elon Musk Says Anthropic Leads AI Race as Claude Models Challenge OpenAI 
SoftBank Corp Partners With Sierra to Expand AI Customer Support Across Japan 
Australia Flags Child Safety Gaps at Apple, Meta, Google Over Online Sexual Extortion 
SK Hynix Shares Drop After Strong Nasdaq Debut Despite $26 Billion ADR Listing 
SK Hynix Soars 13% in Nasdaq Debut After Record $26.5 Billion IPO 
SK Hynix Prices Record U.S. ADR Offering at $149 After $200 Billion Investor Demand 
Morgan Stanley Says China’s Reusable Rocket Progress Poses Long-Term Challenge to SpaceX 
Oppenheimer Sees CNH Industrial as Top 2026 Agriculture Stock Pick on Dealer Consolidation Strategy 
UBS Starts CarTrade Tech With Buy Rating, Sees Strong Earnings Growth and ₹4,000 Target 
BOSTON, Dec. 01, 2015 (GLOBE NEWSWIRE) -- Keryx Biopharmaceuticals, Inc, (NASDAQ:KERX), a biopharmaceutical company focused on bringing innovative therapies to market for people with renal disease, today announced it will present at the Oppenheimer & Co., Inc. 26th Annual Healthcare Conference in New York City on December 8, 2015 at 9:45 a.m. EST.
A live audio webcast of the presentation will be accessible from Keryx’s website at http://investors.keryx.com within the Investor Relations section under the “webcasts and presentations” page. An archived version of the webcast will be available for at least 15 days following the conclusion of the live presentation.
About Keryx Biopharmaceuticals, Inc.
Keryx Biopharmaceuticals, with offices in Boston and New York, is focused on bringing innovative therapies to market for patients with renal disease. In December 2014, the company launched its first FDA-approved product, Auryxia™ (ferric citrate) for the control of elevated serum phosphorus levels, or hyperphosphatemia, in patients with chronic kidney disease (CKD) on dialysis, in the United States. In January 2014, ferric citrate was approved for the treatment of patients with all stages of CKD in Japan, where it is being marketed as Riona® by Keryx's Japanese partner, Japan Tobacco Inc. and Torii Pharmaceutical Co. Ltd. In September 2015, the European Commission granted European market authorization for Fexeric® (ferric citrate coordination complex) for the control of hyperphosphatemia in adults with non-dialysis and dialysis-dependent chronic kidney disease. For more information about Keryx, please visit www.keryx.com.
KERYX CONTACT: Lora Pike Senior Director, Investor Relations T: 617-466-3511 [email protected]
